Vaccination remains the strongest defense against COVID-19. For more information about where you can schedule a vaccine, be tested for COVID-19 or learn more about the virus, visit

COVID-19 Information
Select the search type
  • Site
  • Web


The prophylactic monoclonal antibody therapy for COVID-19, tixagevimab/cilgavimab (Evusheld), recently authorized by the FDA under an emergency use authorization (EUA) is now available from BJC HealthCare and Washington University School of Medicine. This intramuscular antibody cocktail is indicated for use in high-risk patients to prevent COVID-19 infection.

Please note that pre-exposure prophylaxis with Evusheld is not a substitute for vaccination. Individuals for whom COVID-19 vaccination is recommended, including those with moderate to severe immune compromise, should receive the COVID-19 vaccination prior to Evusheld treatment.

Eligibility Criteria | Pediatric Patients | Adult Patients | EUA Fact Sheet

Who is Eligible?

Monoclonal Antibody Therapy for Pre-Exposure Prophylaxis
Inclusion Criteria (must meet all criteria) Exclusion Criteria (if meets any one criterion)

• Moderate to severe immune compromise due to a medical condition (see below) or receipt of immunosuppressive medication or treatments AND may not amount an adequate immune response to COVID-19 vaccination


• COVID-19 vaccination is not recommended due to history of severe adverse reaction

• Less than 12 years of age

• Less than 40 kg

• Currently infected with SARS-CoV-2

• Exposure to someone with SARS-CoV-2 within 10 days

As with other COVID-19 therapies, Evusheld is allocated at the federal and state levels. During times of supply or logistical constraint, patients will be prioritized according to the NIH prioritization tiers. Supply is currently sufficient to offer Evusheld to all patients that qualify under the EUA.

Moderate to severe immunocompromising conditions include, but are not limited to:

  • Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20mg prednisone or equivalent per day when administered for ≥2weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)
Important Evusheld Timing Considerations
Received Not yet received / If going to administer Recommended interval between

COVID-19 Vaccine


2 weeks

Monoclonal antibody for treatment of COVID-19


30 days


COVID-19 Vaccine

Any time, though ideally vaccine should be given 2 weeks prior to Evusheld


Monoclonal antibody for treatment of COVID-19

Any time

Pediatric Patients - Follow These Steps:

Evusheld is available at St. Louis Children’s Hospital for qualifying pediatric patients 12-18 years old and patients who are followed by St. Louis Children’s Hospital providers. Please use the link below for eligibility and ordering information.

Pediatric Quick Reference for Evusheld Epic Hip Tip for ordering Evusheld for pediatric patients

Adult Patients - Follow These Steps:

There are two options for patients to receive treatment: administer in their physician’s clinic or be sent to select BJC/WashU Infusion Centers administering Evusheld. Details on both options are below:

Administering in Physician Clinics (Adult Patients Only)

This is the preferred option for those clinics who meet the criteria below for storing and administering the drug. This option is ideal for patients as they are familiar with your clinic and staff and is sustainable into the future.

Practices can administer in clinic if they are able to store and administer the medication, specifically if the clinic:

  • Is a BJC HealthCare or Washington University School of Medicine practice
  • Has allergic reaction drugs, like epinephrine auto-injector, and staff to administer
  • Has a medication-only refrigerator that is monitored for out-of-range temperatures with 24/7 response
  • Has trained nursing staff to administer the medication using this guide.

BJC will send Evusheld to your clinic weekly on an ongoing basis.

Once drug is received, follow these steps to begin administering in your clinic:

Order for Treatment in select BJC/WashU Infusion Centers

For practices that can’t administer on-site, BJC HealthCare will administer at select BJC clinics as supply allows.

Steps for patients to be treated in select BJC/WashU Infusion Centers clinics:

  • The practice must consent eligible and interested patients.
  • Order the treatment ​

    Epic Hip Tip for ordering Evusheld in BJC/WashU Infusion Centers

  • Referred patients will be treated in these clinics on a first-come-first served basis while supply lasts. We may move to a lottery allocation if demand at these sites far exceeds supply.
  • The infusion sites will call and schedule patients who are referred for treatment. Please communicate with your patients that it may take a few weeks to be scheduled for treatment.
  • For providers who are not on Epic, please contact the desired infusion center to request a paper order form.

EUA Fact Sheet

4901 Forest Park Avenue
St. Louis, Missouri 63108
Copyright © 1997- 2022 BJC HealthCare. All Rights Reserved.